829 related articles for article (PubMed ID: 33657296)
1. Diffuse Large B-Cell Lymphoma.
Sehn LH; Salles G
N Engl J Med; 2021 Mar; 384(9):842-858. PubMed ID: 33657296
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.
Tueger S; Chen FE; Ahsan G; McDonald V; Andrews VE; Madrigal JA; Kazmi MA
Haematologica; 2006 Jun; 91(6 Suppl):ECR16. PubMed ID: 16785122
[TBL] [Abstract][Full Text] [Related]
3. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Hamlin PA; Zelenetz AD; Kewalramani T; Qin J; Satagopan JM; Verbel D; Noy A; Portlock CS; Straus DJ; Yahalom J; Nimer SD; Moskowitz CH
Blood; 2003 Sep; 102(6):1989-96. PubMed ID: 12676776
[TBL] [Abstract][Full Text] [Related]
4. Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era.
Mounier N; Gisselbrecht C
Curr Opin Oncol; 2011 Mar; 23(2):209-13. PubMed ID: 21169834
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
Glass B; Ziepert M; Reiser M; Freund M; Trümper L; Metzner B; Feller A; Loeffler M; Pfreundschuh M; Schmitz N;
Ann Oncol; 2010 Nov; 21(11):2255-2261. PubMed ID: 20444844
[TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin's lymphoma: treatment of large cell lymphomas.
Armitage JO; Carde P; Wolf M
Rev Invest Clin; 1994 Apr; Suppl():83-8. PubMed ID: 7886316
[No Abstract] [Full Text] [Related]
7. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
Moskowitz CH
Ann Oncol; 2006 May; 17 Suppl 4():iv37-9. PubMed ID: 16702184
[TBL] [Abstract][Full Text] [Related]
8. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.
Calvo-Villas JM; Martín A; Conde E; Pascual A; Heras I; Varela R; de la Rubia J; Ramirez MJ; Díez-Martín JL; Panizo C; Rodríguez-Salazar MJ; Pascual MJ; Donato EM; González-Barca E; Caballero MD;
Ann Oncol; 2010 Sep; 21(9):1891-1897. PubMed ID: 20231299
[TBL] [Abstract][Full Text] [Related]
9. Failure of front-line autologous transplant in anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma.
Holtan SG; Feldman AL; Knudson RA; Ketterling RP; Porrata LF
Bone Marrow Transplant; 2011 Jun; 46(6):904-5. PubMed ID: 20818450
[No Abstract] [Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation as first-line consolidation therapy can improve the prognosis of diffuse large B-cell lymphoma with high expression of MYC protein.
Hu K; Gao JJ; Li QH; Tian L; Wan W; Zhao W; Wang JJ; Fu L
Kaohsiung J Med Sci; 2019 Jul; 35(7):425-431. PubMed ID: 31050117
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
12. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
[No Abstract] [Full Text] [Related]
13. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
14. Clinical approach to diffuse large B cell lymphoma.
Caimi PF; Hill BT; Hsi ED; Smith MR
Blood Rev; 2016 Nov; 30(6):477-491. PubMed ID: 27596109
[TBL] [Abstract][Full Text] [Related]
15. The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.
Jurczak W; Długosz-Danecka M; Rivas Navarro F
Future Oncol; 2019 Jan; 15(3):305-317. PubMed ID: 30280924
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.
Maura F; Guidetti A; Pellegrinelli A; Dodero A; Pennisi M; Caprioli C; Testi A; Farina L; Bolli N; Devizzi LF; Cabras A; Corradini P
Blood Cancer J; 2016 Nov; 6(11):e491. PubMed ID: 27813532
[No Abstract] [Full Text] [Related]
17. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
Nabhan C; Mehta J
Leuk Lymphoma; 2012 Oct; 53(10):1859-66. PubMed ID: 22448919
[TBL] [Abstract][Full Text] [Related]
19. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.
Hahn T; Wolff SN; Czuczman M; Fisher RI; Lazarus HM; Vose J; Warren L; Watt R; McCarthy PL;
Biol Blood Marrow Transplant; 2001; 7(6):308-31. PubMed ID: 11464975
[No Abstract] [Full Text] [Related]
20. Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis.
Oh DH; Ghosh S; Chua N; Kostaras X; Tilley D; Chu M; Owen CJ; Stewart DA
Leuk Lymphoma; 2015 Jun; 56(6):1756-62. PubMed ID: 25284495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
